MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound care, showcased its latest advancement—the MolecuLight DX™ multimodal imaging platform—at the St. Louis Wound & Vascular Symposium on June 21, 2025. The platform now features newly integrated thermal imaging capabilities, enhancing its established fluorescence technology. This innovation allows clinicians to simultaneously visualize bacterial presence, monitor skin temperature variations, and measure wound dimensions in real time, directly at the point of care. The result is a single, compact device that delivers a comprehensive picture of wound status—critical for informed and efficient clinical decision-making.

The MolecuLight DX™ platform’s multi-functional imaging tools provide clinicians with highly actionable data. Fluorescence imaging highlights bacterial loads, guiding targeted debridement and microbiological sampling, while the thermal module detects skin temperature variations that can signal inflammation or perfusion issues. Combined with accurate digital wound measurement, the DX™ system enables clinicians to track healing progress over time and tailor interventions with greater confidence. These features not only improve diagnostic accuracy but also support more precise and personalized wound care pathways.

With its powerful new capabilities, MolecuLight’s platform is poised to elevate standards in wound management, reduce reliance on subjective assessments, and improve patient outcomes across care settings. By equipping healthcare providers with real-time, non-invasive visual data, the MolecuLight DX™ supports early intervention, enhances treatment planning, and contributes to more efficient use of clinical resources. As highlighted at the symposium, this breakthrough represents a significant step forward in the integration of imaging technology into routine wound care—and further cements MolecuLight's role as a key innovator in the field.